- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A senior UK-based GSK medical employee ‘loved’ an external LinkedIn post about rectal cancer immunotherapy. Panel said this likely disseminated off-label promotion…
Ex-employee alleged an individual promoted medicines to HCPs for 2+ years without ABPI qualification. Panel found no evidence for the 2-year claim…
At ECCMID 2022, a UK HCP presentation was ruled promotional for Spikevax and included booster-dose data inconsistent with the SPC. Breaches: Clauses…
Complaint alleged a senior AstraZeneca leader’s LinkedIn ‘About’ section promoted POMs to the public and referenced unlicensed indications/trials. Panel ruled no breach…
Ipsen admitted an employee in a promotional role in Northern Ireland had no verified ABPI representative exam on file. PMCPA ruled breaches…
PMCPA ruled GSK’s EAMS press release for dostarlimab was promotional, sent to mainstream media, and promoted an unlicensed indication. Breaches: 5.1, 11.2,…
PMCPA ruled AstraZeneca’s Tagrisso Connect HCP site breached the Code because the first promotional pop-up lacked prescribing information and didn’t clearly signpost…
Complaint alleged Bayer’s US advisory board was disguised pre-licence promotion of Eylea 8mg. Panel initially found breaches, but Appeal Board overturned them…
PMCPA reviewed four AstraZeneca UK corporate tweets about its Covid-19 vaccine. Tweets 1–3 were non-promotional corporate updates. Tweet 4 was ruled promotional…
Anonymous health professional alleged GSK sales aids promoted Trelegy for patients inadequately treated on multiple-inhaler triple therapy (MITT). Panel ruled no breach…
A GP challenged a Takeda promotional leavepiece for pioglitazone that presented benefits as relative risk reduction but harms as absolute risk. The…
Anonymous complaint alleged Trinity-Chiesi sponsored a switch service to Clenil. Panel reviewed the Clinical Support Service documents and process and found no…
A pharmacist challenged an Actonel leavepiece citing NICE July 2008. The Panel found the title and quotations misleading, including an unbalanced risedronate…
A rheumatologist complained that an RCP webcast sponsored by Roche effectively promoted rituximab. The Panel found Roche’s sponsorship was transparent and arm’s…
Servier’s letter, press release and symposium materials implied acid suppressants increased fracture risk and reduced bisphosphonate efficacy. The Panel and Appeal Board…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.